AC
ITRM

Armistice Capital’s Iterum Therapeutics ITRM Stock Holding History

Armistice Capital’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,340,000
Closed -$1.46M – 271
2024
Q3 		$1.46M Buy
+1,340,000
New +$1.59M 0.02% 164
2020
Q3 		– Sell
-84,170
Closed -$1.5M – 113
2020
Q2 		$1.5M Buy
+84,170
New +$3.34M 0.07% 73

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
LF
Lee Financial Dallas, Texas $783M AUM 23.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital's ITRM Position: Q4 2024 in Review

Armistice Capital sold out of Iterum Therapeutics (ITRM) in Q4 2024, closing a stake of 1,340,000 shares — an estimated $1.46M sold.

Armistice Capital first reported a position in ITRM in Q2 2020 and held it in 2 quarters. The position peaked at $1.5M in Q2 2020. 24 funds tracked by Wall St. Rank hold ITRM as of Q4 2024.

  • Armistice Capital reported no remaining Iterum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 1,340,000 Iterum Therapeutics shares in Q4 2024, an estimated $1.46M.
  • Armistice Capital first reported a position in Iterum Therapeutics in Q2 2020 and held it in 2 quarters.
  • Armistice Capital's Iterum Therapeutics position peaked at $1.5M in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.